Shipping out MEK inhibitor resistance with SHP2 inhibitors
P Torres-Ayuso, J Brognard - Cancer discovery, 2018 - AACR
RAS is one of the most frequently altered oncogenes, yet RAS-driven tumors are largely
refractory to anticancer therapies. Fedele and colleagues demonstrate that SHP2 inhibitors
prevent adaptive MEK inhibitor resistance; therefore, combining MEK and SHP2 inhibitors
represents an exciting new therapeutic approach for the treatment of RAS-driven cancers.
Cancer Discov; 8 (10); 1210–2.© 2018 AACR. See related article by Fedele et al., p. 1237.
refractory to anticancer therapies. Fedele and colleagues demonstrate that SHP2 inhibitors
prevent adaptive MEK inhibitor resistance; therefore, combining MEK and SHP2 inhibitors
represents an exciting new therapeutic approach for the treatment of RAS-driven cancers.
Cancer Discov; 8 (10); 1210–2.© 2018 AACR. See related article by Fedele et al., p. 1237.
[引用][C] Shipping out MEK inhibitor resistance with SHP2 inhibitors. Cancer Discov. 2018; 8: 1210–1212. doi: 10.1158/2159-8290
P Torres-Ayuso, J Brognard - CD-18-0915.[Abstract][CrossRef] …